HISTORY
Innovative IVDs Rooted in Tradition
Building on the biotechnology expertise originally cultivated through soy sauce production, Yamasa has developed a range of unique and innovative IVDs.
In particular, we have created and marketed proprietary IVDs in the field of endocrine disorders, including diseases of the thyroid gland and the hypothalamic–pituitary system—areas where our technologies are unmatched.
More recently, leveraging advanced cell engineering techniques, we launched pioneering IVDs that utilize recombinant cells expressing specific proteins. The development of these cell-based IVDs is made possible by our original technologies and is unique within Japan.
With a foundation of innovative and distinctive technologies, our Diagnostics Division is committed to developing, manufacturing, and delivering IVDs that meet diverse medical needs and contribute to building a healthier society.
Connecting “Food” and “Medical Care”: Yamasa’s Journey
Yamasa invented a method for producing nucleic acid–based umami seasonings through the enzymatic degradation of ribonucleic acid (RNA) in the 1950s. Since then, we have established technologies for generating nucleic acid–related substances that play beneficial roles in biological activities. These technologies are now widely applied in pharmaceutical active ingredients and intermediates, as well as in seasonings, cosmetics, and other products.As part of this development, we began research into the roles of nucleic acid–related substances within the human body, which marked the beginning of our work in IVDs.
History of YAMASA Diagnostics
-
- 1645
-
Founded as a soy sauce company
-
- 1957
-
- SEASONING
Established 5'-nucleotides production technology using an enzymatic RNA degradation method
-
- 1970
-
- BIOCHEMICAL
Start manufacturing active pharmaceutical ingredients of nucleic acid related compounds
Initiation of research on the roles of nucleic acid related compounds in vivo, and development of measurement techniques for trace nucleic acid related compounds in vivo.
-
- 1976
-
- RESEARCH
Cyclic AMP KIT "YAMASA" was launched as research use.
-
- 1977
-
- RESEARCH
Cyclic AMP KIT "YAMASA" was launched as research use.
-
- 1981
-
- RESEARCH
Applied the patent of Monoclonal antibody as a first pioneer in Japan.
-
- 1986
-
- ENDOCRINE/METABOLISM
- IVDs
PTH KIT "YAMASA" was launched.
- ENDOCRINE/METABOLISM
- IVDs
Cyclic AMP KIT "YAMASA" was launched.
-
- 1988
-
Diagnostics Department was established.
-
- 1989
-
- CARDIOVASCULAR
- IVDs
MYOSIN LI KIT "YAMASA"was launched.
-
- 1990
-
- BONE METABOLISM
- IVDs
OSTEOCALCIN KIT "YAMASA"was launched.
- CANCER
- IVDs
VMA EIA KIT "YAMASA"was launched.
- CANCER
- IVDs
HVA EIA KIT "YAMASA"was launched.
-
- 1993
-
- AUTOIMMUNITY
- IVDs
Anti-CL-β2GPI KIT "YAMASA"EIA
-
- 1994
-
- CANCER
- IVDs
Tandem PSA was launched.
- BONE METABOLISM
- IVDs
1,25(OH)2D KIT "SRL" was launched.
-
- 1995
-
- ENDOCRINE/METABOLISM
- IVDs
TSAb KIT "YAMASA" was launched.
-
- 1998
-
- RESPIRATORY
- IVDs
SP-D EIA KIT "YAMASA" was launched.
-
- 1999
-
- CANCER
Started to distribute CALTAG Monoclonal and Polyclonal antibodies for flow cytometry in Japan.
-
- 2001
-
- ENDOCRINE/METABOLISM
- IVDs
DYNOtest TRAb Human KIT "YAMASA" was launched.
-
- 2004
-
- CARDIOVASCULAR
- IVDs
MYOSIN LI KIT "YAMASA" EIA Ⅱ was launched.
-
- 2007
-
- RESPIRATORY
- IVDs
SP-D KIT "YAMASA" EIA Ⅱ was launched.
- ENDOCRINE/METABOLISM
- IVDs
INSULIN ANTIBODY KIT "YAMASA" was launched.
-
- 2009
-
- CANCER
Started to distribute DAKO reagents for flow cytometry in Japan.
-
- 2011
-
- CARDIOVASCULAR
- IVDs
Latex H-FABP KIT "YAMASA" was launched.
-
- 2013
-
- ENDOCRINE/METABOLISM
- IVDs
TSAb KIT EIA"YAMASA" was launched.
-
- 2014
-
- CARDIOVASCULAR
- IVDs
CL SP-D KIT "YAMASA" was launched.
-
- 2015
-
- ENDOCRINE/METABOLISM
- IVDs
AVP KIT "YAMASA" was launched.
- ENDOCRINE/METABOLISM
- IVDs
Renin Activity KIT "YAMASA" was launched.
-
- 2020
-
- RESPIRATORY
- IVDs
CL SP-D KIT "YAMASA" NX was launched.
-
- 2021
-
- ENDOCRINE/METABOLISM
- IVDs
Biosensor TSAb "YAMASA"was launched.
-
- 2023
-
- CANCER
- IVDs
Span-1・RIA beads® was launched.
- CANCER
- IVDs
Succeed to PyridnolineⅠCTP.
- BONE METABOLISM
- IVDs
Succeed to Procollagen Intact PⅠNP.
- BONE METABOLISM
- IVDs
Succeed to 1,25(OH)₂D KIT "YAMASA".
-
- 2025
-
- CRANIAL NERVE
- IVDs
Anti-NF155 Antibody "YAMASA"EIA was launched.
- CRANIAL NERVE
- IVDs
Anti-CNTN1Antibody "YAMASA"EIA was launched.
The Future of YAMASA Diagnostics
VISION
We integrate innovative science with precise and flexible manufacturing to address customer needs, create new health value for people worldwide, and help shape a prosperous future society.
MISSION
-
Co-creation with Customers
We accurately capture the true needs of our customers, co-create solutions that bring health and prosperity, and contribute to society.
-
Creating Value
Building on our advanced technologies cultivated through nucleic acid science, we further deepen and integrate them to generate innovative value and new breakthroughs.
-
Passion and Trust
With unwavering passion, we foster mutual trust with our colleagues and customers, working as one team to meet every challenge and see it through to success.